Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directionsNaveen Vasudev, Andrew R. Reynolds|Angiogenesis|2014Cited by 732
ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1AChris T. Williamson, Christopher J. Lord, Helen N. Pemberton et al.|Nature Communications|2016Cited by 386
Elevated Flk1 (Vascular Endothelial Growth Factor Receptor 2) Signaling Mediates Enhanced Angiogenesis in β3-Integrin–Deficient MiceAndrew R. Reynolds, Kairbaan Hodivala‐Dilke|Cancer Research|2004Cited by 153